CTIS.eu › Cities › France › Paris
Paris
France
2,286 total trials
1,022 recruiting
Filter these 2,286 trials by phase, condition, sponsor and more.
Open in Search →
2023-509370-39-00
5
2025-06-03
connective tissue diseases
2024-517819-74-00
9
2025-06-02
Pancreatic Ductal Adenocarcinoma
2023-507936-20-00
5
2025-05-05
Acute myeloid leukemia
2024-517062-42-00
5
2025-05-02
melanoma, cutaneous malignant
2023-505172-29-00
4
2025-04-24
Resectable Non-small Cell Lung Cancer
2024-514459-14-00
4
2025-04-22
Non-Small Cell Lung Cancer
2024-513054-30-00
5
2025-04-16
Moderately to Severely Active Crohn's Disease (CD)
2023-508015-23-00
5
2025-04-11
Ovarian cancer recurrent
2024-511346-39-00
3
2025-03-28
Immune-mediated necrotizing myopathy
2024-512536-29-00
4
2025-02-28
Amyotrophic Lateral Sclerosis (ALS)
2024-515702-63-00
5
2025-02-20
Moderate-to-Severe Active Thyroid Eye Disease
2023-505252-21-00
4
2025-02-14
Hyperkalemia
2024-511900-17-00
3
2025-02-14
Oncology: RELAPSED PRIMARY CNS LYMPHOMA
2024-516339-28-00
4
2025-02-10
EGFR inhibitor-induced folliculitis
2022-501854-12-01
1
2025-02-05
G12D/G12V Pancreatic Ductal Adenocarcinoma
2024-518368-10-00
7
2025-01-29
Recessive dystrophic epidermolysis bullosa (RDEB)
2024-519132-17-00
4
2025-01-29
NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA
2024-513356-15-00
5
2024-12-30
Acquired Blepharoptosis
2024-513077-48-00
5
2024-12-19
O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma
2024-514097-52-00
6
2024-12-16
Impact of inhaled BGF 160 on complexity and variability of tidal breat
2024-511879-16-00
5
2024-12-12
Prurigo Nodularis
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
2024-516393-29-00
5
2024-12-03
Patients colonized with MDR-GNB
2024-514135-17-00
5
2024-11-28
Immunoglobulin A Nephropathy
Showing 337–360 of 2,286 trials